Barclays PLC Grows Position in Biohaven Ltd. (NYSE:BHVN)

Barclays PLC increased its position in Biohaven Ltd. (NYSE:BHVN) by 87.6% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 268,077 shares of the company’s stock after buying an additional 125,189 shares during the quarter. Barclays PLC owned 0.27% of Biohaven worth $13,396,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently made changes to their positions in BHVN. Algert Global LLC grew its holdings in Biohaven by 5.9% in the 2nd quarter. Algert Global LLC now owns 7,402 shares of the company’s stock worth $257,000 after acquiring an additional 412 shares during the last quarter. KBC Group NV boosted its holdings in shares of Biohaven by 24.5% during the third quarter. KBC Group NV now owns 2,250 shares of the company’s stock worth $112,000 after purchasing an additional 443 shares during the period. Hsbc Holdings PLC boosted its holdings in shares of Biohaven by 6.1% during the second quarter. Hsbc Holdings PLC now owns 8,291 shares of the company’s stock worth $286,000 after purchasing an additional 480 shares during the period. Venturi Wealth Management LLC grew its stake in shares of Biohaven by 19.1% in the third quarter. Venturi Wealth Management LLC now owns 3,117 shares of the company’s stock worth $156,000 after purchasing an additional 500 shares during the last quarter. Finally, Arizona State Retirement System increased its holdings in Biohaven by 3.7% during the 2nd quarter. Arizona State Retirement System now owns 20,575 shares of the company’s stock valued at $714,000 after purchasing an additional 730 shares during the period. 88.78% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Biohaven news, Director Gregory Bailey purchased 5,000 shares of the company’s stock in a transaction dated Tuesday, September 24th. The shares were acquired at an average price of $44.19 per share, for a total transaction of $220,950.00. Following the purchase, the director now directly owns 1,620,071 shares of the company’s stock, valued at $71,590,937.49. The trade was a 0.31 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director John W. Childs acquired 21,052 shares of Biohaven stock in a transaction dated Wednesday, October 2nd. The stock was bought at an average price of $47.50 per share, with a total value of $999,970.00. Following the completion of the purchase, the director now directly owns 21,052 shares in the company, valued at $999,970. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 16.00% of the company’s stock.

Biohaven Stock Down 4.2 %

Shares of Biohaven stock opened at $38.47 on Monday. Biohaven Ltd. has a twelve month low of $26.80 and a twelve month high of $62.21. The company has a market cap of $3.89 billion, a price-to-earnings ratio of -4.11 and a beta of 1.24. The company’s 50 day moving average is $48.70 and its 200 day moving average is $41.83.

Biohaven (NYSE:BHVN) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($1.70) earnings per share for the quarter, missing the consensus estimate of ($1.67) by ($0.03). Sell-side analysts expect that Biohaven Ltd. will post -8.85 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have weighed in on BHVN shares. Cantor Fitzgerald reiterated an “overweight” rating on shares of Biohaven in a report on Wednesday, October 23rd. William Blair upgraded Biohaven to a “strong-buy” rating in a report on Friday, August 30th. Bank of America lifted their price target on shares of Biohaven from $52.00 to $62.00 and gave the company a “buy” rating in a report on Tuesday, September 24th. Sanford C. Bernstein boosted their price objective on shares of Biohaven from $55.00 to $66.00 and gave the company an “outperform” rating in a research report on Tuesday, September 24th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $61.00 target price (up from $58.00) on shares of Biohaven in a research report on Wednesday, December 4th. Thirteen research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Biohaven has an average rating of “Buy” and an average price target of $63.00.

Biohaven Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.